Extension of comment period for the Prescription Drug-Use-Related Software Federal Register Notice

The Food and Drug Administration will extend or reopen the comment period for the notice entitled “Prescription Drug-Use-Related Software; Establishment of a Public Docket; Request for Comments” (Docket No. FDA-2018-N-3017) following the end of the partial government shutdown.

Contact Information:

Chris Wheeler
Center for Drug Evaluation and Research
Food and Drug Administration
10903 New Hampshire Avenue
Bldg. 51, Rm. 3330
Silver Spring, MD 20993
Tel: 301-796-0151
Email: chris.wheeler@fda.hhs.gov